Search Results

had a great conversation about this position with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals!

had a great conversation about this position with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals!

promising results for metabolic disorders INDIGO Biosciences, INC as a Preferred Supplier at Prendio Crinetics Pharmaceuticals announces executive departure Call for GPCR Papers Deadline: Nov 1, 2024.

Industry News InterAx Biotech's AI platform unlocks new drug designs for diabetes, obesity, and cancer Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 Sosei

Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Corporate Update

peptide QRFP receptor GPR103 Industry News EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner Monlunabant by

November 11th to 17th, 2024 Industry News Centessa Launches Phase 2 Trial of ORX750 for Narcolepsy and IH Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Aelis Farma

Mark discussed this position with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals

Advances in GPCRs: Structure, Mechanisms, Disease, and Pharmacology Industry News Monash University pharmaceutical Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology Crinetics Pharmaceuticals gets grant for patent granted for somatostatin modulators for treating hormone-related

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization --Design Pharmaceuticals, a company redesigning small molecule drug discovery, today announced the closing Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like

July 2022 "Not even a PIPE financing could save X4 Pharmaceuticals from enacting layoffs and trimming

November 2021 Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc Switzerland, November 15, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical pioneering allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals , Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has successfully completed

with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery "Apr.19.2022 Ono Pharmaceutical

Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical The NDA was submitted by Trevena’s partner, Jiangsu Nhwa Pharmaceutical, and follows completion by Nhwa

monoclonalantibodies #drugdiscovery #biotechnology #research #ionchannels #biologics #biotech #pharma #pharmaindustry #pharmaceuticals

accessed this week  across four critical domains: Industry insights:  Neurocrine at Morgan Stanley; Crinetics

GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease Crinetics

Property for Its Series of Treg Depleting anti-CCR8 Antibodies, Including Best-in-class Candidate DT-7012 Crinetics

Biotech Expands Global Intellectual Property Portfolio with Granted Patents in Australia and Singapore Crinetics

Side Effects Driving Pharma Innovation in Oncology: Domain Therapeutics' Success Proven by Science Crinetics

Domain Therapeutics announces the promotion of Stephan Schann to the role of Chief Scientific Officer Crinetics

Born near Venice and trained as a pharmaceutical chemist, Alessandro never imagined himself working at The Early Days: Molecules and Mentors Alessandro began his academic life studying pharmaceutical chemistry

She studied pharmacy with a specialization in pharmaceutical chemistry, a degree that allowed her to

Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical

research in biomedical sciences with the mechanistic understanding of one of the biggest classes of pharmaceutical

"Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical

Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical

Tagging GPCRs expressed in cellular compartments such as the nucleus or endosomes presents several pharmaceutical Overall, the pharmaceutical challenges associated with tagging GPCRs expressed in cellular compartments Pharmaceuticals (Basel, Switzerland), 14(5), 439. https://doi.org/10.3390/ph14050439 Chen, K.

expansion as the leading GPCR immuno-oncology company Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer Rhythm Pharmaceuticals and LG Chem Life Sciences

Geneva, Switzerland, April 6, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical